Myeloma Trial, Recruiting (NCT00106925)

Myeloma Trial, Recruiting NCT00106925 Sponsor: National Heart, Lung, and Blood Institute (NHLBI) Condition: Myeloma

Printed from Voxsanity (voxsanity.com.au) — NCT00106925 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Myeloma

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You received a stem cell transplant from a donor (called an allogeneic transplant) as part of an NHLBI research study at the NIH, and it was either an experimental or standard treatment
Or, in some special cases, you may be eligible if your donor stem cell transplant was done at a different hospital outside the NIH, if your situation is of particular interest to the research team (confirm with trial site)
You have survived at least 3 years since your first stem cell transplant
You are between 7 and 80 years old
If you are an adult, you are able to understand what the study involves and agree to take part by signing a consent form
If you are under 18, a parent or guardian must give written consent, and the study will be explained to you in a way that matches your age and understanding

Who may not be able to join:

There are no additional reasons that would stop someone from joining, as long as they meet all of the requirements listed above

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 27 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Richard W Childs, M.D., National Heart, Lung, and Blood Institute (NHLBI)

Phone: (301) 827-3479

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT00106925

Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Phase: Not Applicable

Status: Recruiting

Condition: Myeloma

Trial contact: (301) 827-3479

More information: https://clinicaltrials.gov/study/NCT00106925

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You received a stem cell transplant from a donor (called an allogeneic transplant) as part of an NHLBI research study at the NIH, and it was either an experimental or standard treatment
Or, in some special cases, you may be eligible if your donor stem cell transplant was done at a different hospital outside the NIH, if your situation is of particular interest to the research team (confirm with trial site)
You have survived at least 3 years since your first stem cell transplant
You are between 7 and 80 years old
If you are an adult, you are able to understand what the study involves and agree to take part by signing a consent form
If you are under 18, a parent or guardian must give written consent, and the study will be explained to you in a way that matches your age and understanding

Who may not be able to join:

There are no additional reasons that would stop someone from joining, as long as they meet all of the requirements listed above

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 27 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

National Heart, Lung, and Blood Institute (NHLBI)

Registry

ClinicalTrials.gov

Start date

22 April 2005

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Assure consistency of care over time for transplant patients such that outcome data can be meaningfully accrued.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov